Cargando…

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

BACKGROUND: Data that directly associate utilization of novel systemic therapies with survival trends in metastatic breast cancer (MBC) are limited. In the setting of de novo MBC, large registry analyses cite positive temporal trends in survival, but the extent to which advances in systemic therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pal, Sumanta K, Dehaven, Mary, Nelson, Rebecca A, Onami, Susan, Hsu, JoAnn, Waliany, Sarah, Kruper, Laura, Mortimer, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526502/ https://www.ncbi.nlm.nih.gov/pubmed/23020297 http://dx.doi.org/10.1186/1471-2407-12-435

Ejemplares similares

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
por: Pal, Sumanta K., et al.
Publicado: (2013)

Conditional Survival in de novo Metastatic Urothelial Carcinoma
por: Pal, Sumanta Kumar, et al.
Publicado: (2015)

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
por: Pal, Sumanta K., et al.
Publicado: (2019)

Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy
por: Dieli‐Conwright, Christina M., et al.
Publicado: (2016)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
por: Mortimer, Joanne E., et al.
Publicado: (2017)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

ATM/RB1 mutations predict shorter overall survival in urothelial cancer
por: Yin, Ming, et al.
Publicado: (2018)

The Impact of Obesity on Breast Cancer Diagnosis and Treatment
por: Lee, Kyuwan, et al.
Publicado: (2019)

Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care
por: Mortimer, Joanne E., et al.
Publicado: (2020)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions
por: Jones, Veronica C., et al.
Publicado: (2022)

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
por: Galsky, Matthew D., et al.
Publicado: (2018)

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma
por: Joshi, Monika, et al.
Publicado: (2016)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Systemic therapy and COVID19: Immunotherapy and chemotherapy
por: Gulati, Shuchi, et al.
Publicado: (2021)

Modern Development of Chemotherapy
Publicado: (1948)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2023)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
por: Malmgren, Judith A., et al.
Publicado: (2017)

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance
por: Gu, Long, et al.
Publicado: (2009)

Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma
por: Lin, Wei-Yu, et al.
Publicado: (2022)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hl4nulkc4m3h36r98105t5pv50